埃普辛生物活性涂层通过促进早期阶段的再内皮质化和抑制光滑肌肉细胞增殖,减少了静脉内皮增生
Wenxu Zhang1, Hao Lin2, Zechao Zhu1
1Department of Neurosurgery, General hospital of Northern Theater Command, Shenyang, China.
PloS one
|March 25, 2025
概括
抑制Epsin,一种在静止症中升高的蛋白质,促进内皮细胞的愈合,并减少光滑肌肉细胞的增殖. 这一策略在血管手术后有望预防静脉支架狭窄.
科学领域:
- 生物医学工程 生物医学工程
- 血管生物学 血管生物学
- 再生医学是一种再生医学.
背景情况:
- 缺血性中风的干预手术受限于复缩,在支架植入后血管的重新收窄.
- 目前的药物释放支架可以损害内皮细胞,延迟愈合并增加血栓形成的风险.
- 与EPS-15相互作用的蛋白1 (Epsin1) 和Epsin2 (Epsin2) 都与血管重塑和复原有关.
研究的目的:
- 研究Epsin在血管缩中的作用,并评估抑制Epsin的治疗潜力.
- 评估Epsin抑制是否促进内皮质化并减少光滑肌肉细胞的增殖.
主要方法:
- 研究了小鼠回动脉结模式中的Epsin表达.
- 在培养的内皮细胞 (EC) 和光滑肌细胞 (SMC) 中与Epsin发生干扰.
- 在使用Epsin短发针RNA (shRNA) 涂层支架的猪动脉模型中评估了Epsin抑制.
主要成果:
- 素表达在内脏增生症 (IH) 的小鼠模型中升高.
- 抑制Epsin增强了EC的扩散和迁移,同时减少了SMC的扩散和迁移.
- 在猪模型中,Epsin shRNA涂层的支架促进了早期的重新内皮质化,并降低了IH.
结论:
- 素在EC和SMC的扩散和迁移中起着至关重要的作用.
- 抑制Epsin是一种有前途的治疗策略,可以预防静脉支架狭窄.
- 针对Epsin的新型疗法可以改善血管干预的长期结果.
相关概念视频
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
139
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
139
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
118
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
118
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
430
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
430